Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study

Parisi, Simone; Peroni, Clara Lisa; Laganà, Angela; Scarati, M.; Ambrogio, Federico; Bruzzone, Maria; Fusaro, Enrico

doi:10.1093/rheumatology/ket019

Cited by 26 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concomitant therapy with a calcium channel blocker and a selective beta blocker has very promising results compared to monotherapy with a calcium channel blocker (p < 0.001) [19]. Phosphodiesterase 5 selective inhibitors such as sildenafil, tadalafil, vardenafil are also widely used for vasomotor disorders due to their vasodilative effects [20]. Selective serotonin re-uptake inhibitors have also been shown to have a positive influence on Raynaud's phenomenon, however, these drugs are not frequently prescribed [20].…”

Section: Treatmentmentioning

confidence: 99%

“…Phosphodiesterase 5 selective inhibitors such as sildenafil, tadalafil, vardenafil are also widely used for vasomotor disorders due to their vasodilative effects [20]. Selective serotonin re-uptake inhibitors have also been shown to have a positive influence on Raynaud's phenomenon, however, these drugs are not frequently prescribed [20].…”

Section: Treatmentmentioning

confidence: 99%

“…The effectiveness of certain endothelin receptor antagonists (ET1-R) is now being evaluated (ambrisentan) [19]. Vasodilatative drugs such as angiotensin-converting-enzyme inhibitors (captopril, enalapril), moxisylyte, buflomedil, beraprost and dazoxiben did not demonstrate any positive therapeutical effects on this condition [20].…”

Section: Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Raynaud’s phenomenon — the clinical picture, treatment and diagnostics

Walecka¹,

Malewska²,

Roszkiewicz³

et al. 2017

Acta Angiologica

View full text Add to dashboard Cite

show abstract

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Raynaud’s phenomenon — the clinical picture, treatment and diagnostics

Walecka¹,

Malewska²,

Roszkiewicz³

et al. 2017

Acta Angiologica

View full text Add to dashboard Cite

show abstract

“…Ambrisentan has also been shown to reduce the incidence of SSc-associated Raynaud's phenomenon (SSc-RP) attacks, albeit it in a study of only six patients (p = 0.01) [107]. Bosentan's effect on SSc-RP has been more extensively studied, with mixed results.…”

Section: Endothelin Receptor Antagonistsmentioning

confidence: 99%

Translating Autoimmune Pathogenesis into Targeted Therapies for Systemic Sclerosis

Russell¹,

Sofat²

2017

Immunopathogenesis and Immune-Based Therapy for Selected Autoimmune Disorders

View full text Add to dashboard Cite

Targeted therapies including tumour necrosis factor α (TNFα) inhibitors have transformed the management of a number of autoimmune conditions over the past 20 years. One autoimmune rheumatological condition with significant potential for the development of targeted therapies is systemic sclerosis (SSc). In this chapter, we use SSc as an example of how research into the pathogenic processes underlying autoimmune conditions can be translated into novel targeted therapies. We review the evidence base for a range of targeted therapies for SSc identified from a systematic literature search, before highlighting a number of studies currently underway.

show abstract

“…74,75 Ambrisentan, in a smaller number of patients, has been shown to decrease digital ulcer burden. 76,77 A clinical trial of macitentan, a new generation of endothelin receptor antagonists, was recently discontinued and the final report is awaited.…”

Section: Case Twomentioning

confidence: 99%